RT @Yale_CRRIT: High brand-name drug prices fall once a generic enters the market. In a new @JournalGIM article, @rgupta729, CRRIT Co-Direc….

@JohnsHopkinsDOM @JHU_HBHI @JohnsHopkinsSPH @JohnsHopkinsSPH @Hopkins_GIM.

More work is needed on the effect of PACE program ownership status on patient outcomes, particularly given growing evidence on the consequences of private equity for patient health.

We found that after the rule change, while overall program growth and enrollment actually slowed, the number of PACE enrollees receiving care from for-profit programs, often with private equity investment, increased primarily due to the entry of new programs.

Historically, PACE programs have been operated by non-profit entities, but a 2016 rule allowed for-profit PACE programs, which may grow PACE by enticing investments and private equity, but with uncertain effects on patient health and outcomes.

PACE is a managed care program financed by capitated government payments that serves adults >55 years who are dual eligible for Medicare and Medicaid and require nursing home level of care. PACE aims to help people meet their needs in the community instead of a nursing home.

We have new work led by Katherine Miller and mentor @healthecon_dan in @Health_Affairs Scholar on the role of for-profit programs and private equity in PACE (Program of All-Inclusive Care for the Elderly):.

RT @CameronGettel: 🚨EDs are critical for persons living with dementia (PLWD). Could EDs be integrated into the CMS GUIDE Model to improve d….

RT @pash22: The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness . https://….

RT @SoyeonKang_PhD: Excited to share my new paper Health Affairs Scholar with Mingqian Liu, @jeromie_b , @rgupta729 and Jerry Anderson on….

CC: @JohnsHopkinsSPH @HopkinsMedicine @Hopkins_GIM @ucsf_library @industrydocs @JHU_HBHI @JHUWelchCenter @HopkinsMedNews.@OslerResidency @BSPH_HPM.

This work was a joint effort with Jason Chernesky, Caleb Alexander, Anna Lembke, @AdamKoon @DrTomori @drdavidmichaels @jgreene2. Summary here as well by @JohnsHopkinsSPH:

We used documents from the UCSF-JHU Opioid Industry Documents Archive @industrydocs to characterize specific industry strategies that allowed unsubstantiated claims to gain legitimacy by the misrepresentation of a scientific foundation to disarm criticism & promote opioid sales.

*New work* in Health Affairs Scholar: We investigate how the opioid industry used scientific articles to influence prescribing of prescription opioids and shape unsubstantiated claims about the benefits of opioids and manufactured doubt about their risks.

RT @reshmagar: Some of my favorite lawyers on a panel for the @drsforamerica FDA Pre-Conference at #NLC2024 - Matt Tracy, former @ColumbiaL….

RT @bmj_latest: The US has seen several lawsuits in the past decade regarding improper payments to physicians and excess targeted marketing….

RT @Yale_CRRIT: Check out CRRIT Co-directors @jsross119 & @reshmagar's latest paper in @bmj_latest:.

RT @bmj_latest: We need to reconsider standards for targeted #pharmaceutical marketing to doctors through speaker programmes, consulting pr….

RT @BMJOncology: "Medical communities in the US and globally must also consider their complicity and wilful ignorance of the true intent of….

RT @pash22: Tackling the excesses of pharmaceutical marketing and promotion via @rgupta729 et al @susan_bewley @Lar….